Perlinganite, concentrate 1 mg/ml 10 pcs 10 pcs

Stenocardia (unstable and vasospastic), acute myocardial infarction, acute left ventricular failure, hypertensive crisis with a background of heart failure, controlled hypotension.

Active ingredient

Composition

1 ampoule with 10 ml of solution for infusion contains 10 mg of nitroglycerin in an isotonic 5% glucose solution.

How to take, the dosage

Perlinganite is administered by IV, via perfusion. Doses are adjusted individually, usually 0.75-10.0 mg/h.

Interaction

When concomitant use with other vasodilators (vasodilators), hypotensive drugs, beta-adrenoblockers, calcium channel blockers, phosphodiesterase type 5 inhibitors used for treatment of erectile dysfunction (e.g., sildenafil), neuroleptics, tricyclic antidepressants, and ethanol may increase the hypotensive effect.

In concomitant use of Perlinganit with dihydroergotamine an increase in concentration of dihydroergotamine in blood may be observed, which leads to enhancement of its hypotensive effect.

In concomitant use of heparin and Perlinganit the effect of heparin may be weakened. The appropriate dose of heparin is selected under control of blood clotting parameters. After discontinuation of Perlinganit infusion a significant decrease in blood clotting may occur, which may require reduction in the dose of heparin.

In concomitant use of Perlinganit solution and tissue plasminogen activator a decrease in blood concentration and effectiveness of the latter has been described.

Special Instructions

Polyethylene, polypropylene, polytetrafluoroethylene, or glass infusion systems should be used (but not polyvinyl chloride or polyurethane, as these adsorb the active ingredient and may require an increased dose).

Contraindications

Acute circulatory failure (shock, vascular collapse); marked hypotension (systolic BP below 95 mm Hg); cardiogenic shock (when concomitant use of drugs with positive inotropic action or balloon counterpulsation).

Side effects

Headache, drowsiness, weakness, decreased BP, tachycardia, nausea, vomiting.

Overdose

Symptoms: sharp decrease in BP, reflex pulse rate, feeling of general weakness, dizziness and lethargy, as well as headache, reddening of the face or upper half of the trunk, nausea, vomiting and diarrhea. When using the drug in high doses (more than 20 mg/kg body weight) methemoglobinemia, cyanosis, dyspnea and tachypnea may develop; increased intracranial pressure with cerebral symptoms may occur.

Treatment: vital organ function should be monitored.

In case of severe arterial hypotension and/or shock increase the circulating blood volume; in exceptional cases, infusion of norepinephrine (noradrenaline) and/or dopamine may be performed. The use of epinephrine (adrenaline) and related substances is contraindicated.

In case of methemoglobinemia, depending on the severity, the following antidotes are recommended: ascorbic acid (1 g or oral or IV as sodium salt); methylene blue (up to 50 mg of 1% methylene blue solution IV); toluidine blue (initial dose of 2-4 mg/kg body weight IV; if necessary, multiple repetitions with hourly intervals of 2 mg/kg body weight). Oxygen therapy, hemodialysis, blood transfusion are indicated.

Similarities